Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2007 Nov;66(11):1473-8.
doi: 10.1136/ard.2007.072447. Epub 2007 Apr 10.

The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice

W Kievit  1 , J Fransen, A J M Oerlemans, H H Kuper, M A F J van der Laar, D J R A M de Rooij, C M A De Gendt, K H Ronday, T L Jansen, P C M van Oijen, H L M Brus, E M Adang, P L C M van Riel
Affiliations
Comparative Study

The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice

W Kievit et al. Ann Rheum Dis. 2007 Nov.

Abstract

Background: Randomised controlled trials (RCTs) evaluating the efficacy of antagonists to tumour necrosis factor alpha (TNFalpha) showed high response percentages in the groups treated with active drugs.

Objective: To compare the efficacy of anti-TNF treatments for rheumatoid arthritis (RA) patients in RCTs and in daily clinical practice, with an emphasis on the efficacy for patients eligible and not eligible for RCTs of anti-TNF treatments.

Methods: First, randomised placebo-controlled trials written in English for etanercept, infliximab and adalimumab for patients with RA were selected by a systematic review. Second, the DREAM (Dutch Rheumatoid Arthritis Monitoring) register with patients starting for the first time on one of the TNF-blocking agents was used. Patient characteristics, doses of medication and co-medication as well as the ACR20 response percentages were compared between RCTs and DREAM data, stratified for trial eligibility.

Results: In 10 of 11 comparisons, the ACR20 response percentages were lower in daily clinical practice than in the RCT active drug group, which was significant in five of 11 comparisons. Only 34-79% of DREAM patients fulfilled the selection criteria for disease activity in the several RCTs examined. DREAM patients eligible for RCTs had higher response percentages than ineligible DREAM patients. ACR20 response percentages of eligible DREAM patients were comparable with the ACR20 response percentages of the RCT active drug group in 10 of 11 comparisons.

Conclusion: The efficacy of TNF-blocking agents in RCTs exceeded the efficacy of these drugs in clinical practice. However, in clinical practice more patients with lower disease activity were treated with TNF-blocking agents compared with those treated in RCTs. For daily practice patients who were eligible for RCTs, responses were more similar to responses reached in RCTs.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None.

References

    1. Bresnihan B. Pathogenesis of joint damage in rheumatoid arthritis. J Rheumatol 199926717–719. - PubMed
    1. Choy E H, Panayi G S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001344907–916. - PubMed
    1. Elliott M J, Maini R N, Feldmann M, Kalden J R, Antoni C, Smolen J S.et al Randomised double‐blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 19943441105–1110. - PubMed
    1. Moreland L W, Baumgartner S W, Schiff M H, Tindall E A, Fleischmann R M, Weaver A L.et al Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)–Fc fusion protein. N Engl J Med 1997337141–147. - PubMed
    1. Barrera P, van der M A, van Ede A E, Kiemeney B A, Laan R F, van de Putte L B.et al Drug survival, efficacy and toxicity of monotherapy with a fully human anti‐tumour necrosis factor‐alpha antibody compared with methotrexate in long‐standing rheumatoid arthritis. Rheumatology (Oxford) 200241430–439. - PubMed

Publication types

MeSH terms